← Back to Search

SGLT2 Inhibitor

Dapagliflozin 10 mg for Aging (SGLT2i Trial)

Phase 1 & 2
Waitlist Available
Led By Carolina Solis-Herrera
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 12 weeks
Awards & highlights

SGLT2i Trial Summary

This trial is testing a new drug to see if it could help people live longer by impacting several basic aging-related processes.

Eligible Conditions
  • Aging

SGLT2i Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
AGE-RAGE Measurement in Plasma
Secondary outcome measures
6 Minute Walking Distance
Grip Strength

Side effects data

From 2017 Phase 3 trial • 321 Patients • NCT02413398
1%
Gingival bleeding
1%
Diabetic gangrene
1%
Myocardial ischaemia
1%
Diabetic metabolic decompensation
1%
Acute myocardial infarction
1%
Musculoskeletal chest pain
1%
Ischaemic stroke
1%
Syncope
1%
Acute coronary syndrome
1%
Chronic obstructive pulmonary disease
100%
80%
60%
40%
20%
0%
Study treatment Arm
Dapagliflozin 10mg QD
Placebo

SGLT2i Trial Design

2Treatment groups
Experimental Treatment
Group I: Nutritional CounselingExperimental Treatment1 Intervention
10 participants with pre-diabetes will be randomized to receive nutritional counseling weekly for 12 weeks
Group II: DapagliflozinExperimental Treatment1 Intervention
10 participants with pre-diabetes will be randomized to the experimental group to receive dapagliflozin 10mg by mouth daily for 12 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dapagliflozin 10 mg
2015
Completed Phase 4
~18150
Nutritional counseling
2016
Completed Phase 3
~1860

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

The University of Texas Health Science Center at San AntonioLead Sponsor
452 Previous Clinical Trials
91,394 Total Patients Enrolled
10 Trials studying Aging
1,277 Patients Enrolled for Aging
National Institute on Aging (NIA)NIH
1,671 Previous Clinical Trials
28,017,043 Total Patients Enrolled
160 Trials studying Aging
75,987 Patients Enrolled for Aging
Carolina Solis-HerreraPrincipal InvestigatorUniversity of Texas Health at San Antonio

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this study the inaugural example of its type?

"Clinical exploration of Dapagliflozin 10 mg began in 2014, with AstraZeneca backing the initial study that involved 700 individuals. Following its successful completion, the drug was granted N/A approval and has since then been engaged in 63 active trials across 235 cities and 50 countries."

Answered by AI

Are there any opportunities for participants to join this trial?

"The research project, which was first made available on June 25th 2020 is currently searching for test subjects. The information has been edited and revised as recently as December 23rd 2021."

Answered by AI

What is the scope of participants involved in this medical experiment?

"Yes, the information on clinicialtrials.gov affirms that this research is in search of participants. Initially posted June 25th 2020 and last updated December 23rd 2021, the study requires 20 individuals from two distinct sites to complete enrollment."

Answered by AI

To what maladies is Dapagliflozin 10 mg typically prescribed?

"Dapagliflozin 10 mg is typically found in pharmaceutical formulations. In addition, it has the potential to be a successful treatment for those with diet and exercise related issues as well as for those who have not responded to monotherapy."

Answered by AI

Who else is applying?

What state do they live in?
Texas
What site did they apply to?
University of Texas Health Science Center at San Antonio
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
SGLT2 Inhibition in Older Obese Adults With Pre-diabetes
2020. "SGLT2 Inhibition in Older Obese Adults With Pre-diabetes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04401904.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top